Search clinical trials for: BRAF inhibitor

Total 64109 results

Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Anaplastic Thyroid Cancer | ATC

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Langerhans Cell Histiocytosis | Erdheim-Chester Disease | LCH | ECD

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

Metastatic Colorectal Cancer | mCRC

China
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States
University Hospital, Caen

Active, not recruiting

Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer (BRAFREC)

Cancer
National Cancer Institute (NCI)

Active, not recruiting

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Malignant Glioma | Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Bezmialem Vakif University

Unknown

BRAF V600E Mutations In Papillary Thyroid Carcinoma

Papillary Thyroid Carcinoma

Turkey
Manisha Shah
National Comprehensive Cancer Network

Completed

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Centre Hospitalier Universitaire de Nice

Unknown

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) (MALT)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV
Medical University of Graz

Completed

Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.

Nevi

Austria
Corporacion Parc Tauli

Completed

APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.

Papillary Thyroid Carcinoma

Spain
Meyer Children's Hospital IRCCS

Recruiting

Subtypes and Prognostic Factors in Erdheim-Chester Disease

Erdheim-Chester Disease

Italy
Stanford University
Novartis Pharmaceuticals

Completed

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Ameloblastoma | BRAF Gene Mutation

United States
University of Aarhus

Completed

Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma

Papillary Thyroid Carcinoma

Denmark
Glycemic Index Laboratories, Inc
DSM Nutritional Products, Inc.

Completed

Effect of Consuming Oat Bran Mixed in Water Before a Meal on Glycemic Responses in Healthy Humans - a Pilot Study

Glucose Intolerance
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Skin Cancer | Melanoma (Skin) | Skin Carcinoma | Skin Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
Institut de Cancérologie de Lorraine

Completed

Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer (CircuLOR-1)

Metastatic Colorectal Cancer

France
Saint Petersburg State University, Russia

Withdrawn

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)

Thyroid Gland Anaplastic Carcinoma

Russian Federation
Peking University
Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China

Recruiting

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (VISIONARY)

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Gastrointestinal Stromal Tumors | Neuroendocrine Tumors | Esophageal Squamous Cell Carcinoma | Biliary Tract Neoplasms | Unknown Primary Cancer | Digestive Cancer

China
National University of Singapore

Recruiting

Building Resilience @ Work Training Among Healthcare Workers (BRAW)

Resilience, Psychological

Singapore
Craig L Slingluff, Jr
Celldex Therapeutics

Active, not recruiting

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)

Melanoma | Ocular Melanoma | Uveal Melanoma

United States
Jinsong Wu

Completed

Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection

Glioma, Malignant

China
TriHealth Inc.
TriHealth Cancer Institute; TriHealth Surgical Institute; TriHealth Ultrasound... and other collaborators

Withdrawn

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Melanoma (Skin) | Tumor Skin | BRAF Gene Mutation | Melanoma Stage IIIb-IVM1a | Metastasis Skin

United States
University of North Carolina, Chapel Hill
University of Maryland, Baltimore; National Eye Institute (NEI); Orbis

Completed

Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial (PTT)

Surgery | Trichiasis

Ethiopia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | BRAF Gene Mutation

United States
Qazvin University Of Medical Sciences

Unknown

Effect of Low Calorie Diet With Rice Bran Oil on Cardiovascular Risk Factors in Hyperlipidemic Patients

Hyperlipidemias

Iran, Islamic Republic of
Poudre Valley Health System
Colorado State University

Completed

Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children

Hyperlipidemias

United States
KU Leuven

Completed

Effect of Different Bran-based Dietary Platforms on the Colon Metabolism in Healthy Volunteers

Healthy

Belgium
University of Houston
Bounceless

Completed

Comparing Sports Bra Design in Full Busted Women

Back Pain | Chest Pain | Neck Pain | Body Image | Weight, Body | Mastalgia | Activity, Motor | Aging Well | Breast Pain | Back Pain, Low | Back Strain

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)

Melanoma

United States
University of Florida
Kellogg's Corporate Citizens Fund

Completed

Wheat Bioactives and Immune Function

Endocrine, Nutritional, Metabolic and Immunity Disorders

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University of Zurich

Recruiting

Subjective and Objective Outcome of ESS in CRSwNP

CRS

Switzerland
DSM Nutritional Products, Inc.

Withdrawn

Effect of Oat Bran on Bowel Function and Appetite (OATGUT)

Gastrointestinal Disorder, Functional
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
Kellogg Company
Tufts University; University of Toronto; University of Saskatchewan; University... and other collaborators

Completed

Study to Determine the Digestive and Physiological Effects of an Extract From Bran in Healthy Men and Women

Healthy

United States
National Cancer Institute (NCI)
Glaxosmithkline Biologicals S.A.

Terminated

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Renal Failure | Solid Neoplasm | BRAF Gene Mutation | Hepatic Complication

United States, Canada
Instituto de Cardiologia do Rio Grande do Sul
Quaker Oats Company; CNPq Universal

Unknown

Impact of Consumption of Oats in Lipid Profile of Children and Adolescents With Dyslipidemia

Atherosclerosis | Hypercholesterolemia

Brazil
University of Aberdeen
Kellogg Company

Completed

Bioactive Phytochemicals From Wheat Bran (WB2001)

Bio-availability of Wheat Bran Phytochemicals in the Human Gut | Bio-availability of Wheat Bran Phytochemicals for the Systemic Circulation

United Kingdom
Bhavana Konda
National Comprehensive Cancer Network

Active, not recruiting

Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Papillary Thyroid Cancer | Follicular Thyroid Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma | BRAF V600K Mutation Present | BRAF NP_004324.2:p.V600E

United States
Beijing Tongren Hospital

Recruiting

Lateral Pedicled Nasoseptal Flaps for Endoscopic Draf III Procedure in Patients With Frontal Sinus Inverted Papilloma

Inverted Papilloma | Draf III Procedure | Naso-septal Flap

China
University of Reading
PepsiCo Global R&D

Completed

Oat Phenolics Bioavailability

Healthy

United Kingdom
University of Sao Paulo

Completed

The Benefits of the Use of a Support Bra in Women Undergoing Coronary Artery By-Pass Graft Surgery

Quality of Life | Pain | Wound Complications

Brazil
Chonbuk National University Hospital

Recruiting

The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement

Immunity

Korea, Republic of
Washington University School of Medicine

Terminated

The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children

Nausea

United States
National Cancer Centre, Singapore

Terminated

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Singapore
National Cancer Institute (NCI)

Active, not recruiting

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditions

United States

Search clinical trials for: BRAF inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations